Some serious money among this lot. Astrazenaca recently put up 2.5 billion for a cancer drug 'acalabrutinib'... there is money out there for the right asset. Interested though in your rationale for bold status.
I certainly believe Pfizer would be interested as they know and market nadolol. I wonder if these companies have real time access to the NIMA asthma trial? Dosing is complete but it won't report until mid 2016. On another note, does anyone know when toxicology will be completed for inhaled 102 and 104 so that we can get FDA IND status? or has this been put on hold through lack of funding?
potential partners in the biosphere, page-2
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $19.91M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $18.52K | 6.172M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 2255548 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 6075131 | 10 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| IVX (ASX) Chart |